Copyright
©The Author(s) 2021.
World J Clin Cases. Sep 26, 2021; 9(27): 7973-7985
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.7973
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.7973
Mitotic rate (mitoses/mm2) | Ki-67 index | Differentiation | |
Neuroendocrine tumor, Grade 1 | < 2 | < 3% | Well |
Neuroendocrine tumor, Grade 2 | 2-20 | 3%-20% | Well |
Neuroendocrine tumor, Grade 3 | > 20 | > 20% | Well |
Neuroendocrine carcinoma, small-cell type | > 20 | > 20% | Poor |
Neuroendocrine carcinoma, large-cell type | > 20 | > 20% | Poor |
Mixed neuroendocrine–non-neuroendocrine neoplasm | Variable | Variable | Variable |
Type 1 | Type 2 | Type 3 | Type 4 | |
Approximate Proportion | 70%-80% | 5% | 10%-25% | Rarely |
Pathogenesis | Increased gastrin levels due to atrophic gastritis. ECL origin | Increased gastrin levels due to gastrinoma. ECL origin | Not known. Mostly ECL origin | Not known. Non-ECL origin |
Location and characteristics | Gastric body and fundus. Often small and multiple | Gastric body and fundus. Often small and multiple | Anywhere. Large and solitary | Anywhere. Large (often larger than type 3) |
Gastrin level | Increased | Increased | Normal | Increased or normal |
Prognosis | Excellent | Good | Bad | Bad |
Treatment | Surveillance without resection, Endoscopic resection, surgery | Endoscopic or surgical resection, resection of gastrinoma | Gastrectomy and regional lymphadenectomy, systemic chemotherapy | Gastrectomy and regional lymphadenectomy, systemic chemotherapy |
- Citation: Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985
- URL: https://www.wjgnet.com/2307-8960/full/v9/i27/7973.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i27.7973